Compare NAZ & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | CDXS |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.3M | 154.4M |
| IPO Year | 1995 | 2008 |
| Metric | NAZ | CDXS |
|---|---|---|
| Price | $10.49 | $1.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.14 |
| AVG Volume (30 Days) | 41.7K | ★ 823.7K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $18.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $10.18 | $0.96 |
| 52 Week High | $13.42 | $2.98 |
| Indicator | NAZ | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 33.94 |
| Support Level | $10.35 | $0.96 |
| Resistance Level | $10.75 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 28.21 | 5.77 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.